Navigation Links
Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
Date:10/26/2012

MIAMI, FL OCTOBER 26, 2012 Philippe Gnreux, MD was presented the TCT 2012 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The award is given each year to a promising researcher in the field of interventional cardiovascular medicine. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiology.

The award honors the memory of Thomas J. Linnemeier, MD, the former chief of the Indiana Heart Institute, senior vice president of New Ventures, and chief medical officer of Vascular Intervention at Guidant Corp. The purpose of the award, which is accompanied by a $10,000 grant, is to encourage the recipient to maintain a continued commitment and dedication to both patient care and academic research.

An outstanding young academician and a prolific writer, Dr. Philippe Gnreux is a practicing Interventional Cardiologist at Hpital du Sacr-Coeur de Montral. Dr. Gnreux also serves as the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center where he leads the lab's coronary, peripheral, and structural imaging analyses and services. He received his medical degree from the Universit de Montral, Qubec, Canada, and is currently pursuing a PhD at Erasmus University in Rotterdam, The Netherlands. His research interests include coronary risk stratification/Syntax score, coronary physiology and imaging, percutaneous aortic valve replacement, transradial intervention, drug-eluting stent innovation, and medical simulation.

The winner was selected by Drs. Sheldon Goldberg, Howard C. Herrmann, John W. Hirshfeld Jr. and Robert L. Wilensky from Philadelphia. Gregg W. Stone, MD and Howard C. Hermann, MD jointly presented the award. Dr. Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Herrmann is Professor of Medicine and the Director of Interventional Cardiology and Cardiac Catheterization Labs at the Hospital of the University of Pennsylvania.

"Dr. Gnreux's tireless commitment to the dual tracks of cardiovascular research and patient care have established him as a rising star in the field, and he is well on his way to becoming a future leader in interventional cardiology," said Drs. Stone and Herrmann.

"We are extremely proud to honor Dr. Philippe Gnreux with the TCT 2012 Young Investigator Award for his exceptional academic achievements and superb clinical skills, as well as his dedication and passion for the field," Martin B. Leon, MD added. Dr. Leon is the Founder of CRF and Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Drs. Leon and Stone both serve as Co-Directors of the Medical Research and Education Division at CRF, and direct the annual TCT scientific sessions.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the XIMA trial presented at TCT 2012
2. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
3. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
4. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
5. Results of the PC trial presented at TCT 2012
6. Results of the POSEIDON trial presented at TCT 2012
7. 1-year results of ADAPT-DES presented at TCT 2012
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
9. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
10. Research presented at TCT 2012 will have significant impact on interventional cardiology
11. Typical IBD patients not represented in research studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
(Date:3/28/2017)... ... ... With expansion and efficiency in mind, Patten Seed Company completed relocation of ... opened in Marshallville in 2006, and a bagging and shipping facility has been in ... Patten Seed operations to the Middle Georgia location from their previous home in Lakeland, ...
(Date:3/28/2017)... ... 28, 2017 , ... Nurse practitioners and physician assistants are ... in the healthcare workforce, according to a survey recently released by PracticeMatch ... candidate leads to healthcare employers of physicians and advanced practice clinicians. , Only ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology ... global market trends of the Chemotherapy Induced Neutropenia for the seven ... Europe ( France , Germany ... , UK) and Japan , as well as ... the world (RoW). The Report covers the therapeutics market ...
(Date:3/28/2017)... 28, 2017  Rosen Law Firm, a global investor ... action lawsuit on behalf of purchasers of Kitov Pharmaceutical ... and/or traceable to Kitov,s initial public offering on or ... open market from November 20, 2015 through February 3, ... seeks to recover damages for Kitov investors under the ...
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
Breaking Medicine Technology: